TORONTO, July 29, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement offering of 400,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross proceeds of $600,000 CAD (the “Offering”). The proceeds of the […]
Category Archives: Pr Newswire
Pr Newswire
Earth Science Tech, Inc., Reports its June 30, 2024, Quarter Results, Recording Over $8.5M in Revenue and $1.07M in Net Profit
30
Jul
Jul
Miami, FL, July 29, 2024 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC: ETST) (“ETST” or “Company”), a holding entity currently focused on the health and wellness industry, today shares its financial results from its quarter ended June 30, 2024. For the three-month quarter ended June 30, 2024, the Company recorded: $1,384,407 in Cash, versus $91,989 […]
30
Jul
Jul
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on […]
Pr Newswire
Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024
30
Jul
Jul
ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will provide a corporate update and […]
30
Jul
Jul
Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024 Mont-Saint-Guibert, Belgium – July 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), […]
SINGAPORE, July 30, 2024 /PRNewswire/ — Acclime, providing businesses with corporate, governance and advisory services globally, is proud to announce a new regional commercial leadership structure which sets the foundation for the next stage of growth for the company. This move underscores Acclime’s commitment to enhancing operational efficiency and regional expertise across its expansive network […]
Leading online lottery service provider enables Australians to enter international lottery draws online SYDNEY, July 30, 2024 /PRNewswire/ — TheLotter Australia is excited to announce a new addition: a user-friendly mobile app, available for both iOS and Android devices. This extension complements the already popular website, offering Australians a simple way to join the world’s […]
SEONGNAM, South Korea, July 30, 2024 /PRNewswire/ — Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical study of BBT-877, a novel autotoxin (ATX) inhibitor for the treatment of idiopathic pulmonary fibrosis […]
SAN JOSE, Calif., July 30, 2024 /PRNewswire/ — DapuStor Corporation, a pioneer in high-performance data storage solutions, announced today that it is expanding its collaboration with Marvell to deliver breakthrough Flexible Data Placement (FDP) technology optimized for Quad-Level Cell (QLC) and Triple-Level Cell (TLC) Solid-State Drives (SSDs). This collaboration aims to revolutionize the storage industry […]
ONTARIO, Calif., July 30, 2024 /PRNewswire/ — Nature’s Miracle Holding Inc. (NASDAQ: NMHI) (“Nature’s Miracle” or the “Company”), today closed its previously announced underwritten public offering of 5,000,000 shares of common stock, par value $0.0001 per share, at a public offering price of $0.24 per share, for aggregate gross proceeds of $1.2 million prior to deducting underwriting […]